tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Cheilitis D002613 2 associated lipids
Respiratory Tract Neoplasms D012142 2 associated lipids
Granulomatosis, Orofacial D051261 2 associated lipids
Nail Diseases D009260 2 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Skin Diseases, Papulosquamous D017444 2 associated lipids
Candidiasis, Invasive D058365 2 associated lipids
Trichomonas Vaginitis D014247 2 associated lipids
Tongue Diseases D014060 2 associated lipids
Neuroaspergillosis D020953 2 associated lipids
Delayed Graft Function D051799 2 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Venous Insufficiency D014689 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Telangiectasis D013684 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
IgA Deficiency D017098 2 associated lipids
Incontinentia Pigmenti D007184 2 associated lipids
Vitiligo D014820 2 associated lipids
Hypopigmentation D017496 2 associated lipids
Eye Infections, Fungal D015821 2 associated lipids
Tumor Lysis Syndrome D015275 2 associated lipids
Rectal Fistula D012003 2 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Pruritus Ani D011538 2 associated lipids
Deglutition Disorders D003680 2 associated lipids
Discitis D015299 2 associated lipids
Fox-Fordyce Disease D005588 2 associated lipids
Collagen Diseases D003095 2 associated lipids
Multiple Pulmonary Nodules D055613 2 associated lipids
Cholecystolithiasis D041761 2 associated lipids
Brachial Plexus Neuritis D020968 2 associated lipids
Vestibular Diseases D015837 2 associated lipids
Lymphomatoid Granulomatosis D008230 2 associated lipids
Paresis D010291 2 associated lipids
Myxedema D009230 2 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Ileal Neoplasms D007078 2 associated lipids
Lichen Planus, Oral D017676 2 associated lipids
Angiofibroma D018322 2 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Necrobiosis Lipoidica D009335 2 associated lipids
Immunoblastic Lymphadenopathy D007119 2 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Mediastinitis D008480 2 associated lipids
Fibroadenoma D018226 2 associated lipids
Mucinoses D017520 2 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Oliguria D009846 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Dickerson JA et al. Tacrolimus and sirolimus in capillary dried blood spots allows for remote monitoring. 2015 Pediatr Transplant pmid:25414084
Rivelli RF et al. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant. 2015 Nephrology (Carlton) pmid:25404086
Jahan A et al. Clinical efficacy and pharmacokinetics of tacrolimus in children with steroid-resistant nephrotic syndrome. 2015 Pediatr. Nephrol. pmid:26135137
Marquezan MC et al. Effect of Topical Tacrolimus in the Treatment of Thygeson's Superficial Punctate Keratitis. 2015 Am. J. Ophthalmol. pmid:26133248
Birdwell KA et al. Assessment of arterial stiffness using pulse wave velocity in tacrolimus users the first year post kidney transplantation: a prospective cohort study. 2015 BMC Nephrol pmid:26133166
Cury Martins J et al. Topical tacrolimus for atopic dermatitis. 2015 Cochrane Database Syst Rev pmid:26132597
Prinz V et al. MRI heralds secondary nigral lesion after brain ischemia in mice: a secondary time window for neuroprotection. 2015 J. Cereb. Blood Flow Metab. pmid:26126863
Izumi Y et al. Two cases of refractory polymyositis accompanied with steroid myopathy. 2015 Mod Rheumatol pmid:24533547
Gallon L et al. Cellular and molecular immune profiles in renal transplant recipients after conversion from tacrolimus to sirolimus. 2015 Kidney Int. pmid:25354238
Pamuk F et al. Evaluation of gingival alterations in rats medicated with cyclosporine A, tacrolimus and sirolimus: a stereological study. 2015 J. Periodont. Res. pmid:25399832
Gordon P and Gooptu B Tacrolimus in idiopathic inflammatory myopathy-associated interstitial lung disease: defining roles and responders. 2015 Rheumatology (Oxford) pmid:25342374
Huang X and Xu B Efficacy and Safety of Tacrolimus versus Pimecrolimus for the Treatment of Atopic Dermatitis in Children: A Network Meta-Analysis. 2015 Dermatology (Basel) pmid:26043855
Milam EC et al. Treatment of Scarring Alopecia in Discoid Variant of Chronic Cutaneous Lupus Erythematosus With Tacrolimus Lotion, 0.3. 2015 JAMA Dermatol pmid:26039539
Shi WL et al. Effects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis. 2015 PLoS ONE pmid:26039043
Wozniak LJ et al. Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation. 2015 Transplantation pmid:26038872
Argudo A et al. Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation. 2015 Transplant. Proc. pmid:26518936
Xia Z et al. Refractory Dyslipidemia After Liver Transplant: Case Study With Successive Histologic Investigations. 2015 Exp Clin Transplant pmid:25924105
Zheng L et al. Simultaneous determination of cortisol, cortisone, 6β-hydroxycortisol and 6β-hydroxycortisone by HPLC. 2015 J Chromatogr Sci pmid:25628347
Gupta G et al. Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction. 2015 Am. J. Transplant. pmid:25988397
Söderlund C and Rådegran G Safety and efficacy of the switch to generic mycophenolate mofetil and tacrolimus in heart transplant patients. 2015 Clin Transplant pmid:25981927
Yahng SA et al. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia. 2015 Biol. Blood Marrow Transplant. pmid:25300871
van Boekel GA et al. Limited sampling strategy for prolonged-release tacrolimus in renal transplant patients by use of the dried blood spot technique. 2015 Eur. J. Clin. Pharmacol. pmid:25980838
de Jonge H et al. The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. 2015 Pharmacogenomics J. pmid:25287072
Jin S et al. Exposure to Radiocontrast Agents Induces Pancreatic Inflammation by Activation of Nuclear Factor-κB, Calcium Signaling, and Calcineurin. 2015 Gastroenterology pmid:25980752
Ratanatharathorn V et al. Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT. 2015 Bone Marrow Transplant. pmid:25285804
Lin YK et al. Using Imiquimod-Induced Psoriasis-Like Skin as a Model to Measure the Skin Penetration of Anti-Psoriatic Drugs. 2015 PLoS ONE pmid:26355594
Kang YZ et al. Autoimmune hepatitis-primary biliary cirrhosis concurrent with biliary stricture after liver transplantation. 2015 World J. Gastroenterol. pmid:25717264
Andrews LM et al. Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients. 2015 Expert Opin Drug Metab Toxicol pmid:25865963
Murata M Prophylactic and therapeutic treatment of graft-versus-host disease in Japan. 2015 Int. J. Hematol. pmid:25864188
Hiraoka S et al. The earliest trough concentration predicts the dose of tacrolimus required for remission induction therapy in ulcerative colitis patients. 2015 BMC Gastroenterol pmid:25925267
Cuervas-Mons V et al. Impact of tacrolimus and mycophenolate mofetil regimen vs. a conventional therapy with steroids on cardiovascular risk in liver transplant patients. 2015 Clin Transplant pmid:25924549
Hategan A and Bourgeois JA Tacrolimus neurotoxicity and the role of the Renin-Angiotensin system. 2015 J Neuropsychiatry Clin Neurosci pmid:25923858
Blasco-Morente G et al. Long-Standing Presternal Plaque. 2015 Actas Dermosifiliogr pmid:25917959
Ferraresso M et al. Relationship between mRNA expression levels of CYP3A4, CYP3A5 and SXR in peripheral mononuclear blood cells and aging in young kidney transplant recipients under tacrolimus treatment. 2015 Pharmacogenomics pmid:25916520
Li JS et al. Angiopoietin-Like-4, a Potential Target of Tacrolimus, Predicts Earlier Podocyte Injury in Minimal Change Disease. 2015 PLoS ONE pmid:26352670
Lin S et al. Interleukin-2 receptor antagonist therapy leads to increased tacrolimus levels after kidney transplantation. 2015 Ther Drug Monit pmid:25162212
Zhu L et al. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients. 2015 Xenobiotica pmid:25869250
Jiang H et al. An acyltransferase domain of FK506 polyketide synthase recognizing both an acyl carrier protein and coenzyme A as acyl donors to transfer allylmalonyl and ethylmalonyl units. 2015 FEBS J. pmid:25865045
Josephson MA et al. American society of Nephrology Quiz and Questionnaire 2014: transplantation. 2015 Clin J Am Soc Nephrol pmid:25862775
Peña C et al. [Secondary acute myeloid leukemia in a lung allograft recipient. Report of one case]. 2015 Rev Med Chil pmid:25860370
Liu S et al. Comparison of tripterygium wilfordii multiglycosides and tacrolimus in the treatment of idiopathic membranous nephropathy: a prospective cohort study. 2015 BMC Nephrol pmid:26637482
Watanabe K et al. The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer's disease. 2015 Mol Brain pmid:26637371
Wang L et al. Effect of CYP3A5 gene polymorphisms on tacrolimus concentration/dosage ratio in adult liver transplant patients. 2015 Genet. Mol. Res. pmid:26634478
Rodríguez-Rodríguez AE et al. Glucose homeostasis changes and pancreatic β-cell proliferation after switching to cyclosporin in tacrolimus-induced diabetes mellitus. 2015 Nefrologia pmid:26299169
Sigurgeirsson B et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. 2015 Pediatrics pmid:25802354
Kurita T et al. The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis. 2015 Lupus pmid:25297551
Birdwell KA et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. 2015 Clin. Pharmacol. Ther. pmid:25801146
Solomon SR et al. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. 2015 Biol. Blood Marrow Transplant. pmid:25797174
Shokati T et al. Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS. 2015 J Vis Exp pmid:26575262
Furie R et al. Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis. 2015 Semin. Nephrol. pmid:26573553
Abe Y et al. Successful Management of Lupus Nephritis with High Titers of Myeloperoxidase Anti-Neutrophil Cytoplasmic Antibodies Using Tacrolimus. 2015 Intern. Med. pmid:26568012
William BM and de Lima M Sirolimus plus calcineurin inhibitors and methotrexate: is more necessarily better? 2015 Leuk. Lymphoma pmid:25065702
Gu L et al. A retrospective study to compare the use of tacrolimus and cyclosporine in combination with adriamycin in post-transplant liver cancer patients. 2015 Cell Biochem. Biophys. pmid:25287673
Ambrosioni J et al. Role of rhinovirus load in the upper respiratory tract and severity of symptoms in lung transplant recipients. 2015 J. Clin. Virol. pmid:25728070
Marcus EA et al. Successful term pregnancy in an intestine-pancreas transplant recipient with chronic graft dysfunction and parenteral nutrition dependence: a case report. 2015 Transplant. Proc. pmid:25724255
Dias PH et al. Effects of immunosuppression with tacrolimus and mycophenolate mofetil on renal histology and function in single kidney rats submitted to ischemia and reperfusion. 2015 Acta Cir Bras pmid:25714692
Guerra Júnior AA et al. Cyclosporine versus tacrolimus: cost-effectiveness analysis for renal transplantation in Brazil. 2015 Rev Saude Publica pmid:25741648
Youbin Z et al. Tumor Necrosis Factor-α-Induced Protein 8-Like 2 Gene Overexpression Prolongs the Survival of Rat Allogeneic Heart Allografts. 2015 Transplant. Proc. pmid:26518962
Schwarz C et al. Tacrolimus, Mycophenolate Mofetil, and Low-Dose Steroids With or Without Interleukin-2 Receptor Antibody Induction Therapy: A Retrospective Cohort Analysis. 2015 Transplant. Proc. pmid:26518948
Ko MS et al. Tacrolimus therapy causes hepatotoxicity in patients with a history of liver disease. 2015 Int J Clin Pharmacol Ther pmid:25740263
Townamchai N et al. A Simple Novel Technique to Estimate Tacrolimus Dosages During the Early Post Kidney Transplantation Period. 2015 Transplant. Proc. pmid:26518946
San Miguel C et al. Immunosuppression Strategies in the Treatment of Hepatocellular Carcinoma in Virgen de las Nieves University Hospital. 2015 Transplant. Proc. pmid:26518930
Cotton D Celebrating the ACP centennial: from the Annals archive. 2015 Ann. Intern. Med. pmid:25560715
Zhao L et al. Bovine serum albumin nanoparticles for delivery of tacrolimus to reduce its kidney uptake and functional nephrotoxicity. 2015 Int J Pharm pmid:25681723
Ramesh M et al. A novel phosphatidic acid-protein-tyrosine phosphatase D2 axis is essential for ERBB2 signaling in mammary epithelial cells. 2015 J. Biol. Chem. pmid:25681440
Pascher A et al. Protein kinase C inhibitor sotrastaurin in de novo liver transplant recipients: a randomized phase II trial. 2015 Am. J. Transplant. pmid:25677074
Tavira B et al. The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients. 2015 J. Hum. Genet. pmid:25673014
Wang Y et al. Justification of noninferiority margin: methodology considerations in an exposure-response analysis. 2015 Clin. Pharmacol. Ther. pmid:25670256
Buendía JA et al. Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients. 2015 Exp Clin Transplant pmid:26450467
Dumortier T et al. Estimating the contribution of everolimus to immunosuppressive efficacy when combined with tacrolimus in liver transplantation: a model-based approach. 2015 Clin. Pharmacol. Ther. pmid:25669933
Kikuchi T et al. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma. 2015 Int. J. Hematol. pmid:26440970
Dai DS et al. Protective Effect of Salvia Przewalskii Extract on Puromycin-Induced Podocyte Injury. 2015 Am. J. Nephrol. pmid:26439819
Ceberio I et al. Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant. 2015 Leuk. Lymphoma pmid:24913499
Xie X et al. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis. 2015 BMC Nephrol pmid:26126806
Aouam K et al. Development of Limited Sampling Strategies for the Estimation of Tacrolimus Area Under the Curve in Adult Kidney Transplant Recipients According to the Posttransplantation Time. 2015 Ther Drug Monit pmid:25627405
Farhangian ME et al. Treatment of Alopecia Areata in the United States: A Retrospective Cross-Sectional Study. 2015 J Drugs Dermatol pmid:26355621
Oguni H and Hayashi M [Topics for authorization of new intravenous antiepileptic drugs and tacrolimus for autoimmune epilepsy]. 2015 No To Hattatsu pmid:26349372
Kawahara T et al. The role of NFATc1 in prostate cancer progression: cyclosporine A and tacrolimus inhibit cell proliferation, migration, and invasion. 2015 Prostate pmid:25631176
Lemaitre F et al. Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells. 2015 Clin. Biochem. pmid:25562187
Palanisamy AP et al. Induction therapy: clinical and quality of life outcomes in aged renal transplant recipients. 2015 Clin Transplant pmid:25557762
Bhadauria D et al. Cryptosporidium infection after renal transplantation in an endemic area. 2015 Transpl Infect Dis pmid:25620388
Luger T et al. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. 2015 Pediatr Allergy Immunol pmid:25557211
Burke MT et al. Genetics and nonmelanoma skin cancer in kidney transplant recipients. 2015 Pharmacogenomics pmid:25616102
Schnitzler F et al. Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort. 2015 PLoS ONE pmid:26288187
Tedesco-Silva H et al. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses. 2015 Am. J. Transplant. pmid:25988935
Al-Harbi NO et al. Treatment with aliskiren ameliorates tacrolimus-induced nephrotoxicity in rats. 2015 J Renin Angiotensin Aldosterone Syst pmid:24737642
Jung JW et al. Long-term result of maintenance treatment with tacrolimus ointment in chronic ocular graft-versus-host disease. 2015 Am. J. Ophthalmol. pmid:25498356
Roberts WK et al. A destructive feedback loop mediated by CXCL10 in central nervous system inflammatory disease. 2015 Ann. Neurol. pmid:26224283
Lawrence MC et al. NFAT targets signaling molecules to gene promoters in pancreatic β-cells. 2015 Mol. Endocrinol. pmid:25496032
Chakraborty S et al. Prediction of in vivo drug performance using in vitro dissolution coupled with STELLA: a study with selected drug products. 2015 Drug Dev Ind Pharm pmid:25494535
Denardi LB et al. Synergistic effects of tacrolimus and azole antifungal compounds in fluconazole-susceptible and fluconazole-resistant Candida glabrata isolates. 2015 Braz. J. Microbiol. pmid:26221097
Kloster-Jensen K et al. Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro. 2015 Transpl. Int. pmid:26046470
Scholz FM et al. Focal metatarsal fistulae syndrome affecting a greyhound dog successfully treated with topical 0.1% tacrolimus ointment. 2015 Vet. Dermatol. pmid:26216245
Koster RA et al. The performance of five different dried blood spot cards for the analysis of six immunosuppressants. 2015 Bioanalysis pmid:26045003
Hauch A et al. Generics: are all immunosuppression agents created equally? 2015 Surgery pmid:26206317
Borda B et al. [Frequency of T-cell mediated rejection in new-onset diabetes after kidney transplantation]. 2015 Orv Hetil pmid:26039918
Albring A et al. Relationship between pharmacokinetics and pharmacodynamics of calcineurin inhibitors in renal transplant patients. 2015 Clin Transplant pmid:25557538
Georgakopoulou EA and Scully C Systemic use of non-biologic agents in orofacial diseases: other immunomodulatory agents. 2015 Oral Dis pmid:24028818
Türkoğlu O et al. Are antimicrobial peptides related to cyclosporine A-induced gingival overgrowth? 2015 Arch. Oral Biol. pmid:25555253
Lancia P et al. Choosing the right dose of tacrolimus. 2015 Arch. Dis. Child. pmid:25416736